Orbital involvement by NUT midline carcinoma: New presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: A case report

6Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: NUT midline carcinoma (NMC) is a poorly differentiated squamous cancer with a median survival at less than 7 months. NMC is resistant to conventional chemotherapies and characterized by rearrangement of the NUT gene. Case presentation: Here, we described a patient who initially presented with epiphora, and an orbit involved NMC. In addition, we for the first time demonstrated that local radiotherapy combined with tyrosine kinase inhibitor (TKI) could significantly inhibit tumor progression in orbital involvement by NMC. Conclusions: Our study for the first time described an orbit involved NMC patient initially presented with epiphora. In addition, we provided an alternative to the management of orbit involved NMC.

Cite

CITATION STYLE

APA

Chai, P., Zhou, C., Jia, R., & Wang, Y. (2020). Orbital involvement by NUT midline carcinoma: New presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: A case report. Diagnostic Pathology, 15(1). https://doi.org/10.1186/s13000-019-0922-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free